The 41 most recent market catalysts affecting $NVS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 19, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis Announces Mid-Term Growth Targets and Pipeline Updates at Investor Day
Novartis held an Investor Day where it unveiled a strategic growth plan, targeting an average annual sales growth of 5% from 2026 to 2031 and aiming for a core profit margin over 4…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 75
Novartis Cosentyx Receives FDA Approval for Polymyalgia Rheumatica
Novartis has secured FDA approval for Cosentyx to treat polymyalgia rheumatica (PMR), marking a significant expansion of the drug's indications. This is important because Cosentyx …
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
EU Medicines Agency Panel Recommends New Indication for Novartis' Cosentyx
The European Medicines Agency (EMA) panel has recommended a new indication for Novartis' blockbuster drug, Cosentyx, for an adolescent skin condition. This is a positive regulatory…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 65
Novartis Reports Positive Phase III Data for Remibrutinib in Chronic Inducible Urticaria
Novartis reported positive 52-week Phase III clinical trial data for its investigational drug, remibrutinib (Rhapsido), in treating chronic inducible urticaria (CIndU). The data sh…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
Novartis Reaches Key Milestone for Ianalumab Ahead of FDA Vote
Novartis has reached a 'key milestone' for its drug candidate ianalumab, which is currently under FDA review. While the specific nature of this milestone is not disclosed, it sugge…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 65
Novartis Presents Two-Year Data for Ianalumab in Sjögren's Disease
Novartis announced positive two-year clinical data for ianalumab, its investigational treatment for Sjögren's disease, at the ACR meeting. The data indicated further improvements i…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 55
Novartis Ranks First in 2026 Access to Medicine Index
Novartis announced its achievement of the top rank in the 2026 Access to Medicine Index, marking it as the first company to lead in all assessed technical areas since 2008. This re…
Nov 7, 2026
Corporate Catalyst
Bearish
Impact 75
Novartis Discontinues Development of Pelacarsen for Atherosclerotic Cardiovascular Disease
Novartis has announced the discontinuation of pelacarsen for atherosclerotic cardiovascular disease after the drug failed to meet its primary endpoints in the Phase 3 Lp(a)HORIZON …
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
Novartis Venture Fund Participates in €40 Million Series A Financing for Anaheim Bio
Anaheim Bio, a newly formed biotechnology company, announced a successful €40 million Series A financing round. This funding is crucial for the company's initial operations and its…
Nov 3, 2026
Corporate Catalyst
Bearish
Impact 55
Novartis Ends Research Collaboration with BioArctic
Novartis has ended its research collaboration with BioArctic, a development reported on November 3, 2026. This termination signifies a change in Novartis's research portfolio and s…
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis Phase III ORION-4 Trial of Pelacarsen Misses Primary Endpoint
Novartis reported that its Phase III ORION-4 trial for pelacarsen, a drug aimed at cardiovascular disease, did not achieve its primary endpoint. This is a significant clinical setb…
Oct 30, 2026
Corporate Catalyst
Bearish
Impact 65
Federal Court Denies Novartis's Motion to Dismiss in Misappropriation Lawsuit
A federal court denied Novartis's motion to dismiss a lawsuit alleging the misappropriation of confidential information and a proprietary ESG investment strategy. This means the ca…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 65
Novartis Enters Strategic Collaboration with Dren Bio for Oncology Research
Novartis Pharma AG, a subsidiary of Novartis AG, has formed a strategic collaboration with Dren Bio, a clinical-stage biopharmaceutical company. The partnership focuses on the disc…
Oct 27, 2026
Corporate Catalyst
Bearish
Impact 75
Novartis Discontinues Late-Stage Trial for Remibrutinib in Myasthenia Gravis
Novartis announced the discontinuation of a late-stage clinical trial for remibrutinib in generalized myasthenia gravis. This decision was based on an internal analysis indicating …
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
Novartis Raises 2026 Core Operating Income Guidance Following Q3 Results
Novartis announced its Q3 2026 results, showing net sales growth but a substantial 59.11% decline in operating profit due to a $1.9 billion impairment charge on del-desiran. Despit…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
Novartis Canada Receives Positive INESSS Recommendation for Kisqali Reimbursement
Novartis Canada secured a positive recommendation from INESSS for the public reimbursement of Kisqali for adult patients with stage II or III HR+/HER2- early breast cancer at high …
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 75
Novartis Announces Positive Six-Year Overall Survival Data for Kisqali in Early Breast Cancer
Novartis released six-year follow-up data from its Phase III NATALEE trial for Kisqali, demonstrating a 20% reduction in the risk of death for patients with HR+/HER2- early breast …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica
Novartis announced that its drug Cosentyx (secukinumab) has received approval from the European Commission for the treatment of polymyalgia rheumatica (PMR). This regulatory milest…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
Novartis secured FDA approval for Rhapsido to treat symptomatic dermographism (SD), a condition causing chronic hives. This is a significant development as Rhapsido is now the firs…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
Novartis has secured FDA approval for Rhapsido (remibrutinib) to treat symptomatic dermographism, marking a significant expansion of the drug's approved uses. This is a positive de…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
The CHMP's positive opinion for Cosentyx's label expansion into Polymyalgia Rheumatica (PMR) is a crucial development for Novartis. This recommendation, if followed by final approv…
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 75
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Novartis announced a mixed bag of news: the termination of its Phase 2 ALS drug trial for VHB937 due to efficacy failure, and the acquisition of Sironax's brain delivery platform f…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 75
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
Novartis's experimental drug for ALS, a devastating neurological disease, failed in clinical trials. This is significant because it represents a setback for the company's pipeline,…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Upgrades Novartis to Hold, Raises Price Target to $136
HSBC analyst Rajesh Kumar upgraded Novartis from a 'Reduce' to a 'Hold' rating, simultaneously raising the price target from $123 to $136. This change in analyst sentiment suggests…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 85
'Major Novartis shareholder calls for board shake-up after drug trial setbacks' - Reuters Exclusive Interview
This headline is a significant corporate catalyst for Novartis (NVS). A major shareholder demanding a board shake-up indicates deep dissatisfaction with current management and stra…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 95
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Novartis's announcement of the pelacarsen Phase III trial failure is a major negative catalyst. The drug's inability to meet its primary endpoint indicates a significant setback in…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. The global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 did not meet its primary endpoint.
The failure of two Phase III trials for pelacarsen and del-desiran is a significant negative catalyst for Novartis. These drugs were considered important pipeline assets, with pela…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Market-Moving News for September 8th
Novartis's announcement of the pelacarsen Phase III trial failure is a significant negative catalyst, directly impacting its stock due to the loss of a potential blockbuster drug. …
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint
Novartis's failed Phase III HARBOR study for Del-Desiran in Myotonic Dystrophy Type 1 is a major setback, directly impacting the company's future revenue potential and R&D pipeline…
Sep 7, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A)
The update on Novartis' Phase 3 results for Pelacarsen is a critical event for the pharmaceutical sector, particularly for companies involved in cardiovascular disease treatments. …
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.
The failure of Novartis's pelacarsen Phase III trial is a significant negative catalyst for the company, as it represents a lost opportunity for a potentially blockbuster drug in t…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis shares are trading higher after the company announced topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.
The positive Phase III trial results for remibrutinib are a significant corporate catalyst for Novartis, directly impacting its stock positively due to the potential for a new, hig…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 85
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Novartis' remibrutinib achieved significant success in its Phase 3 trials for relapsing multiple sclerosis, demonstrating reduced relapse rates and a favorable safety profile. This…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
Novartis' Pluvicto, a radioligand therapy, received FDA approval for an earlier stage of prostate cancer (mHSPC), nearly doubling its eligible patient pool. This is a significant p…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis' Q2 earnings significantly surpassed analyst expectations, driven by robust sales of its priority medicines like Kisqali and Kesimpta, effectively 'silencing generic fears…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis shares are trading higher after the company reported better-than-expected Q2 financial results
This headline is a significant corporate catalyst, directly impacting Novartis's share price due to strong financial performance. Better-than-expected earnings often signal effecti…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 92
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate
Novartis announced its Q2 earnings, revealing adjusted EPS of $2.41, surpassing the $2.13 analyst consensus, and sales of $14.408 billion, exceeding the $14.042 billion estimate. T…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval
Novartis (NVS) has secured full FDA approval for its drug Fabhalta (iptacopan) for primary IgA nephropathy (IgAN), a significant milestone. This approval is based on Phase 3 trial …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.